At a glance
ClinicalIndex Comparison RecordN/ACompleted· 9,284 enrolled
Drug / intervention
Long-acting Muscarinic Antagonists (LAMA) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CITRUS Study (Comparing the Incidence Between Tiotropium and ICS/LABA in Real World Use in South Korea)
In Brief
An observational study evaluating Long-acting Muscarinic Antagonists (LAMA) and Inhaled corticosteroid (ICS)/Long-acting Beta Agonists (LABA) for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 9,284 participants across 1 site.
Detailed Summary
Non-interventional, Single-country study based on existing data from medical records of COPD patients treated with LAMA or fixed dose combination of ICS/LABA
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedNov 2019
Enrollment StartApr 2020
Primary CompletionDec 2020
TodayJul 2026
First PostedNov 21, 2019
Enrollment StartApr 15, 2020
Primary CompletionDec 31, 2020
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 6.6 years ago
Interventions
Long-acting Muscarinic Antagonists (LAMA)drug
drug
Inhaled corticosteroid (ICS)/Long-acting Beta Agonists (LABA)drug
drug